Advertisement

Topics

Biosimilar Agents for Psoriasis Treatment: The Perspective of Portuguese Patients.

08:00 EDT 28th September 2018 | BioPortfolio

Summary of "Biosimilar Agents for Psoriasis Treatment: The Perspective of Portuguese Patients."

Biosimilars are highly similar copies of previously approved original biologic medicines. Their introduction on the market may yield cost reduction. The aim of this study was to evaluate the perspectives of psoriasis patients on biosimilar medications.

Affiliation

Journal Details

This article was published in the following journal.

Name: Acta medica portuguesa
ISSN: 1646-0758
Pages: 496-500

Links

DeepDyve research library

PubMed Articles [41816 Associated PubMed Articles listed on BioPortfolio]

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.

Psoriasis is a chronic, inflammatory multisystem disease that affects up to 3.2% of the US population. This guideline addresses important clinical questions that arise in psoriasis management and care...

Efficacy and safety of Adalimumab after failure of other anti-TNFα agents for plaque-type psoriasis: clinician behaviour in real life clinical practice.

During treatment with biologic agents for psoriasis in a number of patients a failure may occur and discontinuation with transitioning to an other drug or an optimization strategy, consisting in a dos...

Latex hypersensitivity to injection devices for biologic therapies in psoriasis patients.

An allergic reaction provoked by reexposure to an allergen or antigen is known as a type I or immediate hypersensitivity reaction. Latex allergy is a common cause of type I hypersensitivity reactions....

Treatment use and satisfaction among patients with psoriasis and psoriatic arthritis: results from the NORdic PAtient survey of Psoriasis and Psoriatic arthritis (NORPAPP).

There are scarce data in Scandinavia about treatment satisfaction among patients with psoriasis (PsO) and/or psoriatic arthritis (PsA). The number of patients receiving systemic treatment is unknown.

Treatment of Genital Psoriasis: A Systematic Review.

Genital psoriasis affects approximately 63% of psoriasis patients at least once in their lifetime. More than any other area on the body, genital lesions significantly impair patients' psychologic well...

Clinical Trials [5091 Associated Clinical Trials listed on BioPortfolio]

MSB11022 in Moderate to Severe Chronic Plaque Psoriasis

The purpose of this study is to demonstrate equivalence in efficacy and to compare the safety and immunogenicity of an investigational medication called MSB11022 with Humira® in people wi...

Study to Investigate the Efficacy and Safety of Trastuzumab Biosimilar (Herzuma®) Plus Treatment of Physician's Choice (TPC) in Patients With HER-2 Positive Metastatic Breast Cancer Who Progressed After 2 or More HER-2 Directed Chemotherapy

Trastuzumab combined with chemotherapy has been approved as the first line therapy in HER2+ metastatic breast cancer. When patients experienced progression beyond trastuzumab containing th...

Investigating the Utilisation and Effectiveness of Originator and Biosimilar Anti-TNF Agents

An observational study investigating the utilisation and effectiveness of originator and biosimilar anti-TNF agents in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosin...

Pioglitazone in Psoriasis- A Clinical and Molecular Study.

The study will assess the effectiveness of Pioglitazone on cellular and clinical levels in terms of improvement of both skin and systemic manifestations of psoriasis. The investigators as...

PsoBarrierEU - Barrier Analysis of Guideline-Compliant Healthcare for Psoriasis in Europe

Analysis of barriers in psoriasis care from the patient's and the physician's perspective and generation of scientific data on the quality of health care in Sweden, Poland, Spain, United K...

Medical and Biotech [MESH] Definitions

A humanized monoclonal antibody that binds to IL-12 and IL-23 and is used as a DERMATOLOGIC AGENT in the treatment of patients with plaque PSORIASIS who have not responded to other therapies.

A fumarate derivative that is used as a DERMATOLOGIC AGENT in the treatment of PSORIASIS and SKIN DISEASES. It also may be used as an IMMUNOSUPPRESSIVE AGENT in the treatment of MULTIPLE SCLEROSIS.

A glucocorticoid used topically in the treatment of DERMATITIS; ECZEMA; or PSORIASIS. It may cause skin irritation.

Drugs used in the treatment of movement disorders. Most of these act centrally on dopaminergic or cholinergic systems. Among the most important clinically are those used for the treatment of Parkinson disease (ANTIPARKINSON AGENTS) and those for the tardive dyskinesias.

An anthracene derivative that disrupts MITOCHONDRIA function and structure and is used for the treatment of DERMATOSES, especially PSORIASIS. It may cause FOLLICULITIS.

Advertisement
Quick Search
Advertisement
Advertisement

 
DeepDyve research library

Relevant Topics

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...

Alzumab (Itolizumab)
Biocon Launches ALZUMAb™ - a ‘First in Class’ Novel Biologic Treatment for Psoriasis Patients in India • ALZUMAb™-World's first novel anti-CD6 antibody developed by Biocon to address a large unmet need for th...

Biotechnology Products
BioPortfolio lists over 550 biotechnology products - please open http://www.bioportfolio.com/channels?category_id=5 Direct topic pages: Actos Advair Biopharmaceuticals Biosimilars Biotherapeutics GMO Crops Lipitor ...


Searches Linking to this Article